Toroso Investments LLC Purchases 4,518 Shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP)

Toroso Investments LLC increased its holdings in Horizon Therapeutics Public Limited (NASDAQ:HZNP) by 46.0% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 14,338 shares of the biopharmaceutical company’s stock after purchasing an additional 4,518 shares during the period. Toroso Investments LLC’s holdings in Horizon Therapeutics Public were worth $1,565,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of HZNP. Bank of America Corp DE lifted its holdings in shares of Horizon Therapeutics Public by 19.5% in the 4th quarter. Bank of America Corp DE now owns 1,506,499 shares of the biopharmaceutical company’s stock valued at $171,440,000 after acquiring an additional 245,610 shares during the last quarter. Los Angeles Capital Management LLC lifted its stake in shares of Horizon Therapeutics Public by 2.4% in the 1st quarter. Los Angeles Capital Management LLC now owns 149,319 shares of the biopharmaceutical company’s stock valued at $16,297,000 after purchasing an additional 3,507 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Horizon Therapeutics Public by 34.4% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 3,094 shares of the biopharmaceutical company’s stock worth $338,000 after purchasing an additional 792 shares during the period. Ethic Inc. bought a new position in shares of Horizon Therapeutics Public during the 1st quarter valued at approximately $486,000. Finally, Treasurer of the State of North Carolina raised its holdings in Horizon Therapeutics Public by 0.5% during the 1st quarter. Treasurer of the State of North Carolina now owns 101,734 shares of the biopharmaceutical company’s stock valued at $11,103,000 after buying an additional 479 shares during the period. Hedge funds and other institutional investors own 80.37% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on HZNP shares. StockNews.com raised shares of Horizon Therapeutics Public from a “buy” rating to a “strong-buy” rating in a research note on Wednesday. Jefferies Financial Group downgraded shares of Horizon Therapeutics Public from a “buy” rating to a “hold” rating in a research note on Friday, September 1st. Eight equities research analysts have rated the stock with a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of $110.71.

Horizon Therapeutics Public Stock Down 0.0 %

Shares of Horizon Therapeutics Public stock opened at $115.31 on Friday. The company has a debt-to-equity ratio of 0.48, a current ratio of 4.27 and a quick ratio of 4.09. The stock has a market cap of $26.40 billion, a price-to-earnings ratio of 61.66, a PEG ratio of 3.50 and a beta of 1.05. The firm’s 50-day moving average is $106.34 and its two-hundred day moving average is $106.27. Horizon Therapeutics Public Limited has a 1 year low of $60.03 and a 1 year high of $115.70.

Horizon Therapeutics Public (NASDAQ:HZNP) last issued its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported $1.20 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.12 by $0.08. The company had revenue of $945.00 million for the quarter, compared to analyst estimates of $873.52 million. Horizon Therapeutics Public had a net margin of 12.02% and a return on equity of 20.46%. Horizon Therapeutics Public’s revenue was up 7.8% compared to the same quarter last year. During the same period last year, the company posted $1.07 earnings per share. As a group, research analysts expect that Horizon Therapeutics Public Limited will post 4.7 earnings per share for the current fiscal year.

Horizon Therapeutics Public Company Profile

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation.